Myomo (MYO) to Release Quarterly Earnings on Tuesday

Key Points

• Myomo is set to release its Q2 2025 earnings on August 5th, with analysts predicting a loss of ($0.11) per share and revenue of $9.15 million.
• Insiders have shown confidence in the company, with Director Thomas F. Kirk and CEO Paul R. Gudonis both purchasing significant shares, increasing their respective stakes.
• Brokerage ratings are positive, with multiple firms, including Ascendiant Capital and Alliance Global Partners, setting target prices ranging from $8.00 to $11.50 and maintaining "buy" ratings on Myomo's stock.

Myomo (NYSEAMERICAN:MYO - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 5th. Analysts expect Myomo to post earnings of ($0.11) per share and revenue of $9.15 million for the quarter.

Myomo Stock Performance

NYSEAMERICAN:MYO traded down $0.07 during mid-day trading on Friday, hitting $1.87. The stock had a trading volume of 222,818 shares, compared to its average volume of 514,605. Myomo has a twelve month low of $1.83 and a twelve month high of $7.17. The firm has a market cap of $67.10 million, a PE ratio of -12.43 and a beta of 1.39. The stock has a 50 day simple moving average of $2.44.

Insider Buying and Selling

In related news, Director Thomas F. Kirk acquired 50,000 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were bought at an average price of $3.35 per share, for a total transaction of $167,500.00. Following the completion of the transaction, the director directly owned 305,933 shares in the company, valued at approximately $1,024,875.55. This trade represents a 19.54% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Paul R. Gudonis purchased 30,000 shares of the firm's stock in a transaction on Thursday, May 15th. The stock was acquired at an average price of $3.22 per share, for a total transaction of $96,600.00. Following the completion of the transaction, the chief executive officer directly owned 1,051,671 shares of the company's stock, valued at approximately $3,386,380.62. This trade represents a 2.94% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 118,767 shares of company stock worth $390,093. 4.79% of the stock is owned by insiders.

Hedge Funds Weigh In On Myomo

Several institutional investors have recently bought and sold shares of MYO. Jane Street Group LLC lifted its holdings in Myomo by 84.2% during the 1st quarter. Jane Street Group LLC now owns 162,658 shares of the company's stock valued at $782,000 after buying an additional 74,338 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in Myomo by 157.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 49,101 shares of the company's stock valued at $236,000 after buying an additional 30,028 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Myomo during the 1st quarter valued at about $114,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Myomo during the 1st quarter valued at about $75,000. 44.99% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on MYO shares. Ascendiant Capital Markets lifted their price target on shares of Myomo from $11.00 to $11.50 and gave the company a "buy" rating in a research report on Thursday, June 5th. Alliance Global Partners restated a "buy" rating on shares of Myomo in a research report on Thursday, June 26th. Finally, Craig Hallum set a $8.00 price objective on shares of Myomo and gave the company a "buy" rating in a research report on Monday, June 23rd.

Myomo Company Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.